- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Veritas Pharma Enters Into Agreement to Secure ACMPR License and Cannabis Growing Facility
Veritas Pharma (CSE:VRT) has announced that it has signed a letter of intent with Sechelt Organic Marijuana allowing Veritas the exclusive option to acquire a 100 percent ownership of PrivCo pursuant to obtaining an ACMPR/MMPR license and permission issued by Health Canada for the building of a cannabis growing facility. As quoted in the press …
Veritas Pharma (CSE:VRT) has announced that it has signed a letter of intent with Sechelt Organic Marijuana allowing Veritas the exclusive option to acquire a 100 percent ownership of PrivCo pursuant to obtaining an ACMPR/MMPR license and permission issued by Health Canada for the building of a cannabis growing facility.
As quoted in the press release:
Further, and as part of the agreement, Veritas will manage and help facilitate the application process with Health Canada, and will pay all out-of-pocket expenses during the approval process.
The target acquisition (“PrivCo”), currently owns a secure commercial facility and land located in Sechelt, British Columbia, Canada and, since July 4th, 2014, has had an application pending with Health Canada for a new MMPR (Marihuana for Medical Purposes Regulations) license. PrivCo personnel includes an experienced grow master who is currently a ‘designated grower’ under current MMAR licensing guidelines.
Dr. Lui Franciosi (CEO, Veritas Pharma) comments, “This is a win-win scenario for Veritas and its shareholders. We believe this transaction is both tactical and value driven. Further and most importantly, it is representative of the steps we will take to secure and maximize our position along the medical marijuana supply chain.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.